• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    TruLite Health Bolsters Health Equity Expertise with Expanded Leadership Team

    2/18/25 10:50:00 AM ET
    $ARDT
    $DXR
    Hospital/Nursing Management
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $ARDT alert in real time by email
    • Newly appointed President Walter D. Conwell, MD, MBA, poised to broaden reach with healthcare organizations nationwide
    • Two board members bring additional expertise in health equity innovation and regulation
    • Leadership team committed to TruLite's exponential growth potential as only health equity solution addressing clinical bias at point of care

    TruLite Health, developer of the only health equity solution to remediate clinical bias, has expanded the leadership team as the company strengthens artificial intelligence capabilities and scales to meet the needs of hospital systems, educational institutions and other healthcare organizations nationwide.

    Walter D. Conwell, MD, MBA, now serves as president. Previously serving as chief diversity and inclusion officer and associate dean for faculty development at the Morehouse School of Medicine (MSM) in Atlanta, Conwell is lauded for his health equity expertise, having led the development and implementation of a comprehensive equity strategic framework for the institution. He is also a practicing internal medicine, pulmonary disease, critical care medicine and sleep medicine physician. Conwell has published numerous peer-reviewed articles on medical education, health economics and health equity.

    Conwell is focused on expanding the awareness and implementation of TruLite's innovative software, Truity™, which addresses clinical bias at the point of care by driving patient-specific clinical, social and behavioral interventions that lead to improved healthcare outcomes and costs.

    "Through explainable AI and machine learning, TruLite has the potential to evolve health equity initiatives in a way no other solution can," said Conwell. "To help lead an organization through such transformational change is an incredible opportunity, and I'm eager to leverage my medical and institutional background to significantly advance health equity in this country."

    In addition to appointing a new president, TruLite has added two board members:

    • Edmondo Robinson, MD, MBA, is a national leader in digital health and innovation with over 25 years of experience in healthcare delivery, management and leadership. He is a member of the board of directors at Ardent Health Services (NYSE:ARDT) and the University of Vermont Health Network.
    • Caleb DesRosiers, JD, MPA, is a pharmaceutical and managed care services executive with experience in venture capital, regulatory affairs and public policy. He is a member of the board of directors of Daxor Corp (NASDAQ:DXR).

    "We have the right team and technology in place to significantly address health equity at grand scale," said TruLite Founder and CEO Alan Roga, MD. "The demand for our solution is growing as more healthcare organizations understand the multi-faceted impact of health equity and prioritize clinical strategies to improve care while lowering overall costs. Enhancing the expertise on our own team is a pivotal move amid growth opportunities."

    Leveraging the largest health equity knowledge base, TruLite's Truity software directly integrates into electronic health records (EHRs). It provides patient-specific actions and interventions for clinicians, care teams and patients within the workflow. This integration empowers providers to improve equity at the point of care and aligns with regulatory drivers, including the Joint Commission, Centers for Medicare and Medicaid and Food and Drug Administration.

    Learn how Truity works and more about the health equity champions behind TruLite's innovations.

    About TruLite Health

    TruLite Health has developed the first and only health equity platform designed to address systemic inequities at the point of care. Its innovative software – Truity™ – leverages a unique health equity knowledge base, AI and machine learning to drive targeted interventions for diverse patient populations, improve outcomes and reduce costs. More at trulitehealth.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250218781810/en/

    Lena Vivion

    TruLite Health

    (602) 617-7903

    [email protected]

    Get the next $ARDT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ARDT
    $DXR

    CompanyDatePrice TargetRatingAnalyst
    Ardent Health Partners Inc.
    $ARDT
    12/17/2024$20.00Neutral
    Analyst
    Ardent Health Partners Inc.
    $ARDT
    11/6/2024$22.00 → $19.00Buy → Neutral
    BofA Securities
    Ardent Health Partners Inc.
    $ARDT
    10/11/2024$24.00Overweight
    KeyBanc Capital Markets
    Ardent Health Partners Inc.
    $ARDT
    8/12/2024$22.00Buy
    BofA Securities
    Ardent Health Partners Inc.
    $ARDT
    8/12/2024$18.00Buy
    Loop Capital
    Ardent Health Partners Inc.
    $ARDT
    8/12/2024$24.00Overweight
    Stephens
    Ardent Health Partners Inc.
    $ARDT
    8/12/2024$21.00Buy
    Citigroup
    Ardent Health Partners Inc.
    $ARDT
    8/12/2024$23.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $ARDT
    $DXR
    SEC Filings

    See more
    • SEC Form 10-Q filed by Ardent Health Partners Inc.

      10-Q - Ardent Health Partners, Inc. (0001756655) (Filer)

      5/7/25 4:31:36 PM ET
      $ARDT
      Hospital/Nursing Management
      Health Care
    • Ardent Health Partners Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - Ardent Health Partners, Inc. (0001756655) (Filer)

      5/6/25 4:30:35 PM ET
      $ARDT
      Hospital/Nursing Management
      Health Care
    • SEC Form DEFA14A filed by Ardent Health Partners Inc.

      DEFA14A - Ardent Health Partners, Inc. (0001756655) (Filer)

      4/8/25 4:49:14 PM ET
      $ARDT
      Hospital/Nursing Management
      Health Care

    $ARDT
    $DXR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Ardent Health Partners Inc.

      SC 13G - Ardent Health Partners, Inc. (0001756655) (Subject)

      11/14/24 6:07:29 PM ET
      $ARDT
      Hospital/Nursing Management
      Health Care
    • SEC Form SC 13G filed by Ardent Health Partners Inc.

      SC 13G - Ardent Health Partners, Inc. (0001756655) (Subject)

      11/14/24 4:45:09 PM ET
      $ARDT
      Hospital/Nursing Management
      Health Care
    • SEC Form SC 13G filed by Ardent Health Partners Inc.

      SC 13G - Ardent Health Partners, Inc. (0001756655) (Subject)

      11/14/24 4:27:52 PM ET
      $ARDT
      Hospital/Nursing Management
      Health Care

    $ARDT
    $DXR
    Leadership Updates

    Live Leadership Updates

    See more
    • Ardent Health Appoints Robert DeMichiei to Board of Directors

      Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Robert A. DeMichiei to its board of directors. A seasoned leader with over 30 years of experience in financial strategy, healthcare operations, and board governance, Mr. DeMichiei served as executive vice president and chief financial officer at the University of Pittsburgh Medical Center (UPMC) from 2004 to 2020. During his tenure, he played a pivotal role in driving UPMC's financial growth and led numerous strategic initiatives, including mergers and acquisitions, supply chain management, and revenue cycle improvements. Prior to joining U

      4/3/25 5:27:00 PM ET
      $AP
      $ARDT
      $HCAT
      $WAY
      Fluid Controls
      Industrials
      Hospital/Nursing Management
      Health Care
    • Ardent Health Announces Appointment of Chief Operating Officer and Senior Leadership Promotions

      Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Dave Caspers as chief operating officer. In this new role, Caspers will oversee operations across Ardent Health, which includes 30 hospitals and 280 sites of care in six states. He will be responsible for executing on strategic growth initiatives and driving operational excellence at an enterprise level. Caspers will also lead efforts to further optimize and scale the company's consumer-centric operating model across new and existing markets. "We are pleased to welcome Dave to Ardent," said Ardent Health President and CEO Marty Bonick. "His

      3/31/25 4:30:00 PM ET
      $ARDT
      Hospital/Nursing Management
      Health Care
    • Ardent Health Appoints Dave Styblo to Lead Investor Relations

      Ardent Health (NYSE:ARDT) today announced the appointment of Dave Styblo as senior vice president of investor relations. In his new role, Styblo will oversee Ardent's investor relations program and serve as the primary liaison with investors, analysts and financial partners. Styblo brings more than 20 years of investment experience, including time as a sell-side analyst covering the healthcare industry. He previously served as a senior vice president at Jefferies for more than a decade as an equity research analyst with a focus on healthcare services and managed care stocks. Most recently, Styblo served as an independent investor relations advisor to healthcare companies. He began his c

      9/3/24 4:30:00 PM ET
      $ARDT
      Hospital/Nursing Management
      Health Care

    $ARDT
    $DXR
    Financials

    Live finance-specific insights

    See more
    • Ardent Health Reports First Quarter 2025 Results

      Ardent Health Partners, Inc. (NYSE:ARDT) ("Ardent Health" or the "Company"), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced results for the quarter ended March 31, 2025. First Quarter 2025 Operating and Financial Summary All comparisons are versus the same prior year period. See the footnotes to the Operating Statistics table of this press release for definitions of the metrics below and a full list of key operating metrics. Total Revenue $1.50 billion 4.0% growth Y/Y Net Income Attributable to Ardent Health $41 million Adjusted EBITDA(1) $98 million 2.5% growth Y/Y Adjusted EBITDAR(1) $139 million

      5/6/25 4:30:00 PM ET
      $ARDT
      Hospital/Nursing Management
      Health Care
    • Ardent Health Announces First Quarter 2025 Results Conference Call and Webcast Date

      Ardent Health (NYSE:ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced that it will issue its first quarter 2025 results after the market closes on Tuesday, May 6, 2025. A conference call will be held the following day, Wednesday, May 7, 2025, at 10:00 a.m. ET to review the Company's financial results, discuss recent events and conduct a question-and-answer session. A webcast of the conference call and accompanying presentation materials will be available in the Investor Relations section of Ardent's website at ir.ardenthealth.com. To listen to a live broadcast, go to the site at least 15 minutes prior to the scheduled start time

      4/22/25 4:30:00 PM ET
      $ARDT
      Hospital/Nursing Management
      Health Care
    • Daxor Corporation Reports Increase in NAV to $7.25 Per Share and 116.5 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2024

      Strong Start to 2025 with Unaudited Revenue Increases Leading to Cash Flow Positive Operating Company Results Oak Ridge, TN, March 04, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, announces today the filing of its Annual Report to Shareholders on Form N-CSR, disclosing its schedule of portfolio holdings as of December 31, 2024. Management reported a NAV of $7.25 per share for fiscal 2024 versus $7.08 for the comparable period in 2023. The company has reported a successful 2024 and an even stronger start to 2025, driven by a series of strategic advancements in product development, revenue growth, and key acquisitions. D

      3/4/25 4:55:00 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care

    $ARDT
    $DXR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst resumed coverage on Ardent Health Partners with a new price target

      Analyst resumed coverage of Ardent Health Partners with a rating of Neutral and set a new price target of $20.00

      12/17/24 7:27:59 AM ET
      $ARDT
      Hospital/Nursing Management
      Health Care
    • Ardent Health Partners downgraded by BofA Securities with a new price target

      BofA Securities downgraded Ardent Health Partners from Buy to Neutral and set a new price target of $19.00 from $22.00 previously

      11/6/24 7:16:56 AM ET
      $ARDT
      Hospital/Nursing Management
      Health Care
    • KeyBanc Capital Markets initiated coverage on Ardent Health Partners with a new price target

      KeyBanc Capital Markets initiated coverage of Ardent Health Partners with a rating of Overweight and set a new price target of $24.00

      10/11/24 7:35:47 AM ET
      $ARDT
      Hospital/Nursing Management
      Health Care

    $ARDT
    $DXR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Feldschuh Michael Richard bought $16,277 worth of Daxor Common Stock (2,063 units at $7.89), increasing direct ownership by 0.98% to 212,694 units (SEC Form 4)

      4 - DAXOR CORP (0000027367) (Issuer)

      4/7/25 3:23:29 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Director Demichiei Robert was granted 10,073 shares (SEC Form 4)

      4 - Ardent Health Partners, Inc. (0001756655) (Issuer)

      4/4/25 4:47:38 PM ET
      $ARDT
      Hospital/Nursing Management
      Health Care
    • SEC Form 3 filed by new insider Demichiei Robert

      3 - Ardent Health Partners, Inc. (0001756655) (Issuer)

      4/4/25 4:41:50 PM ET
      $ARDT
      Hospital/Nursing Management
      Health Care

    $ARDT
    $DXR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Daxor Announces Duke University Study on Blood Volume Analysis in Heart Failure Published in American Heart Journal

      Published Research Demonstrates the Value of BVA in Meeting Key Goal of Identifying Anemia in Heart Failure Patients Oak Ridge, TN, May 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), Daxor Corporation, the global leader in blood volume measurement technology, today announces significant new findings from Duke University Medical Center published in the prestigious American Heart Journal. The research demonstrates how Blood Volume Analysis (BVA) enables precise measurement of red blood cell mass (RBCM) and effectively differentiates between true and dilutional anemia in heart failure (HF) patients. The detection of true anemia and its management is a key part of Heart Failur

      5/14/25 8:00:00 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Daxor's Blood Volume Analysis Diagnostic Reaches Two New U.S. Healthcare Systems

      Gold-Standard Technology Now Available in East Tennessee and Pacific Northwest Through Strategic Dual-Model Implementation Oak Ridge, TN, May 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), Daxor Corporation, the global leader in blood volume measurement technology, announces the expansion of its innovative diagnostic solutions into two additional U.S. healthcare systems, further advancing the standard of care for cardiovascular and critical care patients nationwide. Daxor continues to drive healthcare transformation through its dual implementation models, tailored to meet the unique needs of diverse clinical settings. This strategic expansion includes: A premier regional r

      5/13/25 8:00:00 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Florida Healthcare Leader Embraces Daxor Blood Volume Analysis Technology

      Daxor's ezBVA Lab Service Marks New Standard in Precision Fluid Management Oak Ridge, TN, May 07, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (NASDAQ:DXR), the global leader in blood volume measurement technology, today announces the opening of a new BVA program at a premier Florida healthcare center in the Tampa Bay region. This expansion integrates Daxor's innovative blood volume analysis (BVA) testing across the facility's inpatient and outpatient care programs, revolutionizing fluid management precision and enhancing treatment outcomes for a spectrum of conditions. The facility will utilize Daxor's state-of-the-art Tennessee-based CLIA-certified ezBVA Lab that delivers comprehensive b

      5/7/25 8:00:00 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care

    $ARDT
    $DXR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Executive Officer Feldschuh Michael Richard bought $16,277 worth of Daxor Common Stock (2,063 units at $7.89), increasing direct ownership by 0.98% to 212,694 units (SEC Form 4)

      4 - DAXOR CORP (0000027367) (Issuer)

      4/7/25 3:23:29 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Chief Executive Office Feldschuh Michael Richard bought $8,130 worth of Daxor Common Stock (1,000 units at $8.13), increasing direct ownership by 0.48% to 210,631 units (SEC Form 4)

      4 - DAXOR CORP (0000027367) (Issuer)

      3/27/25 11:46:12 AM ET
      $DXR
      Medical/Dental Instruments
      Health Care
    • Amendment: Chief Executive Officer Feldschuh Michael Richard bought $11,518 worth of Daxor Common Stock (1,492 units at $7.72), increasing direct ownership by 0.72% to 208,984 units (SEC Form 4)

      4/A - DAXOR CORP (0000027367) (Issuer)

      3/20/25 5:09:37 PM ET
      $DXR
      Medical/Dental Instruments
      Health Care